Meridian Bioscience (VIVO) to Release Quarterly Earnings on Friday

Meridian Bioscience (NASDAQ:VIVOGet Rating) is set to post its quarterly earnings results before the market opens on Friday, May 6th. Analysts expect Meridian Bioscience to post earnings of $0.48 per share for the quarter.

Meridian Bioscience (NASDAQ:VIVOGet Rating) last announced its quarterly earnings data on Friday, February 4th. The company reported $0.35 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.25 by $0.10. Meridian Bioscience had a net margin of 19.14% and a return on equity of 18.45%. The business had revenue of $88.34 million for the quarter, compared to analyst estimates of $73.75 million. During the same period in the prior year, the firm posted $0.65 EPS. On average, analysts expect Meridian Bioscience to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Shares of Meridian Bioscience stock opened at $27.46 on Thursday. The stock has a market capitalization of $1.20 billion, a P/E ratio of 20.19 and a beta of 0.34. Meridian Bioscience has a twelve month low of $17.00 and a twelve month high of $28.72. The company has a current ratio of 4.08, a quick ratio of 2.59 and a debt-to-equity ratio of 0.14. The business’s fifty day moving average price is $26.16 and its 200 day moving average price is $22.67.

In related news, EVP Lourdes Weltzien sold 20,000 shares of the stock in a transaction dated Tuesday, February 15th. The stock was sold at an average price of $25.60, for a total value of $512,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew S. Kitzmiller purchased 4,028 shares of Meridian Bioscience stock in a transaction dated Friday, February 25th. The stock was bought at an average cost of $24.87 per share, with a total value of $100,176.36. The disclosure for this purchase can be found here. 2.30% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. grew its holdings in Meridian Bioscience by 1.7% during the fourth quarter. BlackRock Inc. now owns 7,405,925 shares of the company’s stock valued at $151,081,000 after purchasing an additional 120,338 shares during the last quarter. Meros Investment Management LP bought a new stake in shares of Meridian Bioscience in the 4th quarter worth approximately $6,740,000. Morgan Stanley boosted its stake in Meridian Bioscience by 10.3% during the third quarter. Morgan Stanley now owns 196,201 shares of the company’s stock worth $3,775,000 after buying an additional 18,351 shares in the last quarter. Legal & General Group Plc increased its stake in Meridian Bioscience by 3.4% in the fourth quarter. Legal & General Group Plc now owns 103,866 shares of the company’s stock valued at $2,119,000 after acquiring an additional 3,382 shares during the period. Finally, Deutsche Bank AG boosted its holdings in Meridian Bioscience by 205.6% during the fourth quarter. Deutsche Bank AG now owns 84,175 shares of the company’s stock valued at $1,717,000 after purchasing an additional 56,630 shares in the last quarter. Hedge funds and other institutional investors own 94.72% of the company’s stock.

A number of research analysts have recently commented on VIVO shares. StockNews.com began coverage on shares of Meridian Bioscience in a research report on Thursday, March 31st. They set a “buy” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Meridian Bioscience in a report on Friday, April 8th. Finally, Zacks Investment Research upgraded shares of Meridian Bioscience from a “hold” rating to a “buy” rating and set a $31.00 price target on the stock in a research report on Wednesday, April 13th.

Meridian Bioscience Company Profile (Get Rating)

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H.

Featured Stories

Earnings History for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.